EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Early versus standard anti-thymocyte globulin administration in haploidentical transplantation using post-transplant cyclophosphamide: a pilot comparative study

Ghazaleh Kheiri, Negar Nejati, Kobra Bagheri Valami, Bita Shahrami, Sahar Tavakoli, Neda Alijani, Arash Safari Sabet, Maryam Barkhordar

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-07147-1 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Hematology, 2026. Verfasst von Ghazaleh Kheiri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Cyclophosphamide, Transplantation, Haploidentical, Peripheral Blood Stem Cell Transplantation. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combining rabbit anti-thymocyte globulin (ATG) with post-transplant cyclophosphamide (PTCy) reduces graft-versus-host disease (GVHD) after haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) but may increase cytomegalovirus (CMV) reactivation due to intensified immunosuppression. Because ATG exposure at the time of graft infusion is influenced by administration timing, we evaluated whether earlier ATG delivery modifies CMV outcomes while maintaining comparable observed transplant outcomes in this small pilot cohort. In this single-center, non-randomized pilot study, 36 adults with acute leukemia undergoing first myeloablative haplo-PBSCT with a uniform ATG/PTCy platform were analyzed. The intervention cohort received rabbit ATG 2.5 mg/kg/day on days - 9 to - 7 (n = 18), while the control cohort received the same total dose on days - 3 to - 1 (n = 18). All patients received busulfan/cyclophosphamide conditioning, PTCy (40 mg/kg on days + 3 and + 4), and cyclosporine. Letermovir was not used. The primary endpoint was CMV reactivation (> 500 copies/mL) within 90 days. The primary endpoint was not met: The 90-day cumulative incidence of CMV reactivation was similar between early and standard ATG cohorts (55.6% vs. 59.3%; p = 0.94). Early ATG was associated with numerically lower peak CMV viral loads (median 995 vs. 1,456 copies/mL; p = 0.86) and fewer cases of high-level viremia ≥ 1,000 copies/mL (22.2% vs. 33.3%). Neutrophil and platelet engraftment occurred earlier with early ATG (median 12.5 vs. 15 days, p < 0.001; and 14 vs. 17 days, p = 0.042). Rates of grade III-IV acute GVHD (11.1% in both groups), relapse, non-relapse mortality, and two-year overall survival were comparable. Exploratory analyses suggested numerically lower CMV viral burden and faster hematopoietic recovery in the early ATG cohort, but these observations are hypothesis-generating only. Given the non-randomized design, historical control, and limited sample size, no conclusions regarding efficacy preservation or superiority can be drawn. Confirmation in larger, prospective, ideally randomized studies incorporating immune monitoring is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antilymphocyte SerumCyclophosphamideTransplantation, HaploidenticalPeripheral Blood Stem Cell TransplantationHumansPilot ProjectsFemaleAdultMaleMiddle AgedGraft vs Host DiseaseCytomegalovirus InfectionsImmunosuppressive AgentsCytomegalovirusYoung AdultVirus ActivationTransplantation ConditioningRabbits

Stichwörter der Autor:innen

Anti-thymocyte globulinCytomegalovirusEngraftmentGraft-versus-host diseaseHaploidentical transplantationPost-transplant cyclophosphamide

Substanzen

Antilymphocyte SerumCyclophosphamideImmunosuppressive Agents

Autor:innen und Institutionen

  • Tehran University of Medical Sciences, Tehran, Iran.
  • School of medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
  • Hematologic Malignancies Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Infectious Disease, Dr. Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Tehran University of Medical Sciences, Tehran, Iran. barkhordarm.n@gmail.com.
  • Tehran University of Medical Sciences, Shariati Hospital, Tehran, 1411713131, Kargar-e-Shomali Ave., Iran. barkhordarm.n@gmail.com.

Zitieren

APA

Kheiri, G., Nejati, N., Valami, K. B., Shahrami, B., Tavakoli, S., Alijani, N., Sabet, A. S., & Barkhordar, M. (2026). Early versus standard anti-thymocyte globulin administration in haploidentical transplantation using post-transplant cyclophosphamide: a pilot comparative study. Annals of Hematology. https://doi.org/10.1007/s00277-026-07147-1

Vancouver

Kheiri G, Nejati N, Valami KB, Shahrami B, Tavakoli S, Alijani N, et al. Early versus standard anti-thymocyte globulin administration in haploidentical transplantation using post-transplant cyclophosphamide: a pilot comparative study. Annals of Hematology. 2026. doi:10.1007/s00277-026-07147-1

BibTeX
@article{Kheiri2026,
  author = {Kheiri, Ghazaleh and Nejati, Negar and Valami, Kobra Bagheri and Shahrami, Bita and Tavakoli, Sahar and Alijani, Neda and Sabet, Arash Safari and Barkhordar, Maryam},
  title = {Early versus standard anti-thymocyte globulin administration in haploidentical transplantation using post-transplant cyclophosphamide: a pilot comparative study},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-07147-1}
}
Kostenlos starten →